Radiopharma release into Europe: Key Considerations

Here are a number them to consider;

1. Key definitions linked to Radiopharma products

Radiopharmaceutical products are medicines that contain radioactive materials.They can come in many different forms, for example as injectable solutions (the most common), capsules or oral solutions and indeed as inhalation products.

A radiopharmaceutical consists of two parts;

• A radioactive isotope (radionuclide), which emits radiation;
• A carrier molecule that directs the radioisotope to a specific organ, tissue, or cellular receptor.

They are used mainly for diagnosis or treatment of diseases, most commonly in nuclear medicine. Diagnostic radiopharmaceuticals are used in small doses and emit gamma rays or positrons, detectable by scanners or imaging equipment  (the likes of  a PET or SPECT scanner) and these detects where the product goes in the body. This helps doctors see things like how organs are functioning, or if there are tumor present.

Examples include:

• Fluorodeoxyglucose (FDG) with fluorine-18: used in PET scans to spot cancer or brain disorders. The Fluorine-18 FDG is a glucose analog so it accumulates in areas with high metabolic activity such as the location of tumours;
• Technetium-99m compounds: super common for imaging bones and heart.

Therapeutic radiopharmaceuticals: the radiopharmaceutical delivers cytotoxic radiation directly to a targeted area (like a tumor) to kill or shrink it, without harming too much of the surrounding healthy tissue.

Examples:

• Iodine-131: used to treat thyroid cancer or an overactive thyroid.
• Lutetium-177 used to treat neuroendocrine tumours
• Strontium-89 chloride – relief of cancer bone pain

2. What makes Radiopharma unique compared to more traditional therapies

Radiopharmaceuticals are unique and powerful medical tools because they combine targeted biological activity along with radioactive energy, (biology and physics)  enabling precise diagnosis and therapy at the molecular level

They do things that regular drugs can’t.

1. First example – They let doctors truly see inside the body to see what’s happening. : Unlike CT or MRI, which show structure, radiopharmaceuticals provide functional or metabolic information about tissues and diseases — often before structural changes appear. FDG PET detects cancer based on glucose metabolism long before a tumor is large enough to see anatomically. This gives doctors earlier diagnosis, better for patients, more accurate disease staging and better assessment of treatment response.
2. They can target and treat disease with extreme precision: Radiopharmaceuticals can be uniquely engineered to selectively bind to specific molecular markers or physiological processes within the body.

How this works:

• A carrier molecule (like a peptide, antibody, or small molecule) is designed to seek out and bind to specific targets (receptors, enzymes, cell types). PSMA
• A radioisotope is chemically attached to the carrier.
• The compound is administered to the patient and accumulates at the intended site (e.g., tumor, bone lesion, or organ).
• This means radiation is delivered precisely to the site of interest with minimal effect on healthy tissues
• Different radiation types can be utilized, e.g. alpha or beta emitters, depending on the requirements, high energy, short range, longer tissue penetration

1. They are special as they can serve as both diagnostic and therapeutic purposes – a concept called theranostics. Some agents can be used for both finding and treating disease — sometimes even in one visit! (Example: using one radioactive agent to spot a tumor, and another to destroy it.)
2. Despite the product being categorized as “radioactive” they are extremely safe are minimally invasive compared to other treatment options (e.g. surgery) and there is less risk of toxicity compared to chemotherapy for example and more targeted than external beam radiotherapy.

Most commonly used isotopes are chosen for their short physical and biological half-lives, which means: They perform their task and decay quickly. The patient’s radiation exposure is low. There is no long-term radioactivity in the body.

• F-18: 110 minutes (used in PET scans, cleared quickly)
• Lu-177: 6.7 days (enough time to treat tumors but manageable in radiation safety protocols)

Radiopharmaceuticals represent a convergence of nuclear physics, radiochemistry, molecular biology, and clinical medicine.

Their uniqueness lies in their ability to:

• See disease from the inside out
• Treat it with pinpoint accuracy
• Do both in a single molecule

3. What are the “Board Level” challenges that Radiopharma companies?

1. Regulatory Complexity

Radiopharmaceuticals are dual regulated;

1. as pharmaceuticals by agencies such as the EMA in Europe and MHRA in UK
2. and as radioactive materials by nuclear regulatory bodies.
3. Challenge of Annex 1 compliance for Sterile Manufacturing and operator protection – lead shielding, lead pots, shield syringes is real! Experts in Contamination control and radioprotection etc . Navigating complex and overlapping regulatory frameworks without delaying product development or market access.
4. Supply Chain Fragility

Many isotopes are produced in only a few global facilities, often tied to aging nuclear reactors or high-cost cyclotrons. What this means: Any reactor outage or transport disruption can cause global shortages. Scaling therapeutic isotope supply can be particularly difficult and costly.

Competition for isotopes is growing as more therapies enter the pipeline. For example: Mo-99, which decays to Tc-99m (used in >80% of diagnostic scans), is produced at only a few reactors worldwide. The global supply crisis in 2009 revealed how dependent the system is on just a handful of sources.

EMA published paper recently on tackling vulnerabilities of supply chains of RadioPharma with EU:https://www.ema.europa.eu/en/news/tackling-vulnerabilities-supply-chain-radiopharmaceuticals-eu

1. Talent Shortage

Finding qualified people (radiochemists, nuclear pharmacists, regulatory experts, QPs) is tough and competitive. Radiopharma demands multidisciplinary expertise but these professional are in short supply globally and training programs can be limited. Some companies need to operate on a small pool of experienced personnel.

1. Public Perception and Radiation Fear

Radiopharmaceuticals are still niche compared to traditional pharma. Despite the scientific safety profile the term radioactive triggers anxiety and mistrust for patients and staff.  Patient education and market education is important for companies for these truly unique medicines.

4. What are the operational challenges linked to radiopharma products?

These are the “on-the-ground” issues that teams wrestle with every day:

1. Short Half-Lives = Urgency Everywhere

Some isotopes decay in minutes or hours (e.g., Fluorine-18: half-life ~110 minutes). Production, QC, packaging, shipping — all must happen extremely fast. Super-fast deviations and OOS management!

1. Specialized Manufacturing Processes

Production must happen in shielded environments (hot cells, isolators, shield syringe, lead pots). Sterility, purity, and radiation containment must be assured every batch. Radiation Safety Compliance Workers need constant monitoring (dosimeters). Robust management of radiopharma waste.

1. Complex Logistics

Transporting radioactive materials involves licensed couriers, radiation compliance, and tight timing. For importation into Europe a site of importation is required, and customs clearance along with QP batch certification. A delayed with a flight or any of the subsequent steps can result in a wasted batch and delayed scan or treatment. For cancer treatments, days and weeks can be critical.

Operates in a just in time production – cant stock pile.

1. Quality Control and Conditional Releases

Every dose must pass QC tests for radioactivity, chemical and radiochemical purity and endotoxins etc. QC must be very fast but extremely reliable. 14-day sterility test will not be known until after the patient has been administered their dose…

5. Key considerations linked to releasing Radiopharma products into the EU/UK and how MIAS Pharma is able to support

1. Awareness of Regulatory challenges associated with the Marketing authorization or Clinical trial authorization to get things off the ground and approval.

MIAS can support with supply chain mapping as per of the application. If marketed product, provide audit and QP declaration for API, support PQS MAH, support with setting up WDA and provision of an RP. EU point of contact for quality defects and recalls For investigational medicinal products, support with IMPD, audit and QP declaration for sites outside the EU.

1. Awareness that to import a radiopharmaceutical a Manufacturing Import Authorization (MIA) is required.

Need to ensure batch certification by a Qualified Person (QP) before the product can be released to the market or a hospital. MIAS holds an MIA for batch certification of marketed and IMP products.

MIAS also has a number of QPs who specialize in radiopharmaceuticals and can work flexibly and remotely to ensure tight timelines are meet and certify your product into both the EU and UK

A physical site of importation is required as per EU Annex 21 and MIAS partners with a number of these sites who specialize in importation, handling and customs clearance of radiopharmaceuticals.

1. Awareness of the challenges of navigating the complexity of EU GMP regulations.

Radiopharmaceuticals must comply with requirements for Eudralex Volume 4 (and 10 as applicable), includes Annex1, sterile manufacture, Annex 3 specific to radiopharmaceuticals and Annex 21, importation to name a few.

MIAS can expertly guide through the specific EU requirements with a  compliance driven but pragmatic approach, We can provide inspection readiness audit and gap analysis of your PQS to ensure your best chance of being EU / UK ready.

1. Awareness of the implication for distribution and handling radiopharmaceuticals within EU.

Companies must comply with ADR (European road transport rules for radioactive materials) and air shipment restrictions.

MIAS partners with a number of transport and handling companies who specialize in this activity and who can support  the importation and customs clearance of radiopharmaceuticals to ensure no delays.

6. Site of Importations, transport and distribution partners – what criteria would you use to ensure they have all critical components in place?

Key criteria include;

1. The right Site of Importation with the right authorisations: MIA as physical site of importation, lists radiopharmaceuticals, perform audit, review processes and procedures and track record in importing these types of products. Location is everything.
2. Transport and distribution partners – registration for importation of radioactive materials transport license for radioactive materials. Country by country requirements
3. ISO accreditation
4. Review fleet of vehicles and contingency plans

7. How would you typically adapt your batch certification processes to Radiopharma products?

 Typically work back from the patient dose!

1. Your dose filled at T0 will be very different by day 4 for example;
2. Review may be evening or weekends to accommodate for time differences where CMO is located. Work remotely, fully electronic;
3. Production review as soon as documents become available;
4. Not all QC tests may be available (sterility);
5. Batch review is measured in hours not days – urgency, time critical;
6. Pragmatic approach to devs, OOS and good communication with SMEs to get to the root of the problem quickly and understanding of impact to patient safety, product quality and efficacy. We do not have the luxury of time but equally, so standards of quality are not reduced;
7. Come armed with solutions!